Navigation Links
Prenatal Antidepressants Don't Raise Fetal, Infant Death Risk: Study
Date:1/2/2013

WEDNESDAY, Jan. 2 (HealthDay News) -- Women who take certain antidepressants while pregnant do not raise the risk of a stillbirth or death of their baby in the first year of life, according to a large new study.

The findings stem from an analysis involving 30,000 women in Denmark, Finland, Iceland, Norway and Sweden, who gave birth to more than 1.6 million babies, in total, between 1996 and 2007. Close to 2 percent of the women took prescription selective serotonin reuptake inhibitors (SSRIs), such as Prozac (fluoxetine) and Paxil (paroxetine), for depressive symptoms during their pregnancy.

The research team, led by Dr. Olof Stephansson of the Karolinska Institute in Stockholm, Sweden, reports in the Jan. 2 issue of the Journal of the American Medical Association that initially women taking an SSRI for depression did seem to experience statistically higher rates of stillbirth and infant death. However, that uptick in risk disappeared once they accounted for other factors, including the threat posed by depression and the mother's history of psychiatric disease or hospitalizations, the authors noted in a journal news release.

"The present study of more than 1.6 million births suggests that SSRI use during pregnancy was not associated with increased risks of stillbirth, neonatal death or postneonatal death," Stephansson's team reported.

"The increased rates of stillbirth and postneonatal mortality among infants exposed to an SSRI during pregnancy were explained by the severity of the underlying maternal psychiatric disease and unfavorable distribution of maternal characteristics such as cigarette smoking and advanced maternal age," the authors added.

Depression during pregnancy affects between 7 percent and 19 percent of mothers-to-be in economically developed countries, the authors pointed out in the report. "Maternal depression is associated with poorer pregnancy outcomes, including increased risk of preterm delivery, which in turn may cause neonatal morbidity and mortality," they explained.

The team acknowledged that use of SSRIs during pregnancy has been associated with birth defects, neonatal withdrawal syndrome and pulmonary hypertension of the newborn, which is what led to the current study, they said.

Although they found that the drugs posed no independent risk regarding stillbirth or infant death, the authors urged mothers and physicians to approach SSRI use carefully.

"Decisions regarding use of SSRIs during pregnancy must take into account other perinatal outcomes and the risks associated with maternal mental illness," Stephansson and colleagues concluded.

More information

For more on antidepressants, visit the U.S. National Library of Medicine.

-- Alan Mozes

SOURCE: Journal of the American Medical Association, news release, Jan. 1, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Prenatal tests more informative using microarray technology, find GW researchers
2. Documenting womens experiences with chromosome abnormalities found in new prenatal test
3. Illy Trieste Science Prize: Yuk Ming Dennis Lo awarded for non-invasive prenatal diagnosis
4. Prenatal diagnosis of congenital heart disease increases maternal stress, depression, and anxiety
5. Prenatal exposure to pesticide additive linked with childhood cough
6. Prenatal maternal smoking associated with increased risk of adolescent obesity
7. Prenatal Exposure to Common Household Chemical Linked to Eczema
8. Prenatal exposure to common household chemical increases risk for childhood eczema, study says
9. Prenatal exposure to pollution especially dangerous for children with asthma
10. When Antidepressants Dont Work, Give Counseling a Try
11. Common Antidepressants Tied to Higher Bleeding Risk in Warfarin Users: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prenatal Antidepressants Don't Raise Fetal, Infant Death Risk: Study
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology: